Figure 2. Quality of life (QOL) scores for functional scale items

Slides:

Advertisements

Similar presentations

From: An open day in the metric space

Advertisements

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Fig. 1 Graphical representation

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

From: Political Leadership and Power Redistribution

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Source:Ellerman, Convery, and de Perthuis (2010). Figure 6. 2, p

pSS: primary SS; Scl: scleroderma.

Figure 1. Selection of papers.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

From: Unmasking Masks in Makkah: Preventing Influenza at Hajj

Figure 1 (A) Chest computed tomography scans of the patient

Figure 1. Hepatitis B surface antigen (HBsAg) testing uptake and results among women delivering at Bairo Pite Clinic in Dili, Timor-Leste. From: Prevalence.

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

From: Grammatical rhymes in Polish poetry: A quantitative analysis

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

Fig. 1. Timeline of the CPAP in Ghana study.

From: Where do we go from here

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Figure 1 Study flowchart.

Figure 1 Flow chart of search and selection strategy for studies in a systematic review of endometrial thickness during IUI with ovarian stimulation. *

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Examples of e-cigarette discussions in social media

From: Estimating the Location of World Wheat Price Discovery

Figure 1. Time of initiation of therapeutic hypothermia according to who initiated it. Note the logarithmic scaling of the vertical axis. From: Initiation.

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 2 Comparison of pregnancy outcomes between true NC-FET and modified NC-FET. Odds ratio (OR) adjusted for clinical pregnancy (OR 0.90, 95% CI 0.73–1.12)

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 6. RRs for clinical cure rates stratified by different diseases

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

(A–B) Images of US ... (A–B) Images of US assessment of both patients who developed peripheral arthritis during vedolizumab treatment undergoing US-guided.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Take home figure The protective role of CNP/NPR-B/NPRC.

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Figure 1. CONSORT diagram.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 2. Quality of life (QOL) scores for functional scale items Figure 2. Quality of life (QOL) scores for functional scale items. **P value <0.05 (using paired T test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10):2241-2249. doi:10.1093/annonc/mdq749 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 1. Overview of the clinical trial. From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10):2241-2249. doi:10.1093/annonc/mdq749 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 3. Quality of life (QOL) scores for symptom scales items Figure 3. Quality of life (QOL) scores for symptom scales items. **P value <0.05 (using paired T test), ##P value <0.05 (using T test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10):2241-2249. doi:10.1093/annonc/mdq749 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 4. Immune cells in study and control group. #P value <0 Figure 4. Immune cells in study and control group. #P value <0.05 (using Wilcoxon signed- ranks test). *P value <0.05 (using Mann–Whitney test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10):2241-2249. doi:10.1093/annonc/mdq749 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 5. Cytokine-secreting cells (ELISPOTS/10<sup>^</sup>6 peripheral blood mononuclear) in study and control groups. #P value <0.05 (using Wilcoxon signed- ranks test). *P value <0.05 (using Mann–Whitney test). From: The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring Ann Oncol. 2011;22(10):2241-2249. doi:10.1093/annonc/mdq749 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com